There are two take-home messages from FDA's latest meeting on patient-focused drug development: lung cancer patients are undeterred by potential risks if a treatment has any potential to extend life, and the agency may struggle to get input from the majority of patients, who are too sick to travel.

The half-day lung cancer meeting on June 28 was FDA's third meeting under its Patient-Focused Drug Development Initiative. It included both small cell and non-small cell lung cancer.